Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Gill

Sports Medicine Dedham, MA Medical Doctor

NPI 1457339491 CMS profile 21038

40 Allied Dr, Dedham, MA 02026

Open in the dashboard

General payments

$168,260

213 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Gill of Dedham, MA is reported in the CMS Open Payments database as having received $168,260 across 213 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22,897 39
2024 General $54,134 23
2023 General $30,713 48
2022 General $15,641 27
2021 General $21,951 34
2020 General $6,609 12
2019 General $16,314 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Gill
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Thomas Gill were reported at $22,897. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Thomas Gill Sports Medicine median Middle half National median
2019 $16,314 $1,176 $199–$4,249 $163
2020 $6,609 $708 $96–$2,890 $114
2021 $21,951 $1,213 $152–$3,994 $132
2022 $15,641 $1,230 $159–$3,998 $149
2023 $30,713 $584 $146–$2,836 $160
2024 $54,134 $628 $163–$3,168 $164
2025 $22,897 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $95,679 56 payments
  2. Linvatec Corporation $32,413 10 payments
  3. DePuy Synthes Products, Inc. $27,697 15 payments
  4. Smith+Nephew, Inc. $2,916 11 payments
  5. Stryker Corporation $2,837 25 payments
  6. Vericel Corporation $1,317 8 payments
  7. DePuy Synthes Sales Inc. $735 17 payments
  8. Exactech, Inc. $506 3 payments
  9. Zimmer Biomet Holdings, Inc. $450 10 payments
  10. Vertex Pharmaceuticals Incorporated $366 13 payments
  11. Other $3,343 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $153,415 24 payments
  2. Food and Beverage $10,493 164 payments
  3. Travel and Lodging $4,327 24 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25 1 payment
Products named General payments · program years 2019–2025
  1. HEALIX KNOTLESS PEEK $100,817 30 payments
  2. BIOBRACE 23MM $30,596 8 payments
  3. DYNACORD $21,619 7 payments
  4. HEALIX $19,708 6 payments
  5. GRYPHON $17,038 10 payments
  6. RIGIDLOOP Sports Surgical $16,048 3 payments
  7. RIGIDLOOP Sports Surgical $8,222 13 payments
  8. Gryphon Orthocord $6,532 3 payments
  9. LINVATEC SHOULDER ARTHROSCOPY $3,086 5 payments
  10. MACI $1,285 7 payments
  11. Other $11,591 157 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

98

Median for Orthopedic Surgery: 203

Drug cost

$207

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 51 $153
Tramadol Hcl Generic 47 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$92,163

Of which drugs: $335

Medicare patients

238

Average age 72

Services billed

970

121 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 74%
High blood pressure 59%
Depression 21%
Diabetes 18%
Ischemic heart disease 18%
Chronic kidney disease 13%
Cancer 13%
Atrial fibrillation 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 79 476 $335

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

213 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record